Skip to content


    Attention All WebMD Community Members:

    These message boards are closed to posting. Please head on over to our new WebMD Message Boards to check out and participate in the great conversations taking place:

    Your new WebMD Message Boards are now open!

    Making the move is as easy as 1-2-3.

    1. Head over to this page:

    2. Choose the tag from the drop-down menu that clicks most with you (and add it to any posts you create so others can easily find and sort through posts)

    3. Start posting

    Have questions? Email us anytime at

    MS Drugs May Not Delay Disability - More Contradictory News
    Elizabeth_WebMD_Staff posted:
    According to a new study, patients treated with interferon beta, the drugs to help prevent relapses, were no less likely than untreated patients to progress to the point where they required a cane.

    Multiple Sclerosis Drugs May Not Delay Disability

    Researches in British Columbia and Italy appear to have conflicting results. Once again, we hope that wider, comprehensive research is conducted.

    Share your thoughts on this news.

    hackwriter responded:
    The research community is already aware that we don't all respond equally to interferons or to glatiramer acetate. These conflicting studies might be a reflection of that.

    There is a recent study published in the July 12 issue of the New England Journal of Medicine about the discovery of a particular kind of antibody found in the blood of MS patients that are not present in other autoimmune diseases, the significance of which is that it might help to identify what kinds of drugs will benefit us via a blood test during the diagnostic phase. Getting the right treatment early in the disease process might help us delay having to use a walking aid.

    Elizabeth_WebMD_Staff replied to hackwriter's response:
    Hi Kim -

    I also noticed that study last week but think I read about it in Neurology???? Oh, and you also posted about it here -

    Scientists Pinpoint Antibody that may be Specific to MS

    This antibody news seems like it would take center stage over some of these other small patient population studies.

    hackwriter replied to Elizabeth_WebMD_Staff's response:

    I agree that the antibody study is more significant and builds on the genetic studies that are identifying biomarkers for MS.

    The overall significance of these is that they will help move treatment trends from a once-size-fits-all therapy to individualized treatment, one that delivers a "molecular cocktail" designed especially for that patient.


    Featuring Experts

    Stephanie knows multiple sclerosis as a patient and as a nurse. Stephanie was diagnosed with multiple sclerosis in 2013. Shortly after being diagnosed...More

    Helpful Tips

    certified nursing assistant (CNA)
    I am a care giver who have had vast experience with MS patient and i do travel with my client/s. If some one out there who is looking for a ... More
    Was this Helpful?
    2 of 2 found this helpful

    Related Drug Reviews

    • Drug Name User Reviews

    Report Problems With Your Medications to the FDA

    FDAYou are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.